🏛️ Verified NIH Record • Updated 2026-07-30
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) (NCT04021108)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Weill Medical College of Cornell University
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
Who can join: Review the eligibility criteria below.
Location: Moffitt Cancer Center — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Moffitt Cancer Center — Tampa, Florida
- Washington University School of Medicine — St Louis, Missouri
- University of Nebraska — Omaha, Nebraska
- Roswell Park Cancer Center — Buffalo, New York
- Weill Cornell Medicine — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastroesophageal Adenocarcinoma
- RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial — Montreal,
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas — Los Angeles, California
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) — Orange, California
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — Newark, Delaware
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma — Calgary, Alberta
Explore by condition: All Gastroesophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.